CDX2 is highly expressed in various gastrointestinal cancers, such as colorectal adenocarcinomas (70–85%), gastroesophageal (50%), stomach (55–70%), ampulla (65–80%) and small intestine tumors (60%) [20, 46]. Here, CDX2 is linked to small intestine neoplasm.